Influenza virus vaccine - Biologic Drug Details

Summary for influenza virus vaccine

Tradenames:	3
High Confidence Patents:	0
Applicants:	3
BLAs:	4
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for influenza virus vaccine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for influenza virus vaccine

Recent Clinical Trials for influenza virus vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Tongji Hospital	NA
Henry M. Jackson Foundation for the Advancement of Military Medicine	PHASE4
U.S. Food and Drug Administration (FDA)	PHASE4

See all influenza virus vaccine clinical trials

Recent Litigation for influenza virus vaccine

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc.	2024-12-13
ACQIS LLC v. Hon Hai Precision Industry Co., Ltd.	2023-04-10
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC	2021-11-10

See all influenza virus vaccine litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for influenza virus vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for influenza virus vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	AGRIFLU	influenza virus vaccine	Injection	125297	10,143,767	2034-06-12	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AGRIFLU	influenza virus vaccine	Injection	125297	10,213,485	2035-08-27	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AGRIFLU	influenza virus vaccine	Injection	125297	10,369,219	2035-08-04	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AGRIFLU	influenza virus vaccine	Injection	125297	10,406,209	2036-09-26	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AGRIFLU	influenza virus vaccine	Injection	125297	10,772,922	2037-11-03	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AGRIFLU	influenza virus vaccine	Injection	125297	11,452,771	2040-09-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for influenza virus vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	10,047,116	2032-10-01	Patent claims search
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	10,124,056	2035-08-18	Patent claims search
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	10,130,697	2031-03-23	Patent claims search
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	10,149,901	2036-01-27	Patent claims search
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	10,195,266	2035-09-14	Patent claims search
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	10,369,210	2035-09-18	Patent claims search

International Patents for influenza virus vaccine

Country	Patent Number	Estimated Expiration
Australia	2003267433
Ukraine	87494
South Korea	20060096981
China	103554104
Australia	2007258202
Austria	E551993

Influenza Virus Vaccine Biologic: Market Dynamics and Financial Trajectory

Last updated: April 26, 2026

Influenza virus vaccines are a high-volume, recurring seasonal biologic with pricing driven by government procurement, payer formularies, and contract bundling. Financial performance is shaped by annual supply-and-demand balance, antigen composition updates, vaccine category mix (egg-based vs cell-based vs recombinant), and the extent of stockpiling and government tender volatility. Recent years show a market that is stable in volume but cyclic in revenue, with profits concentrated in a limited set of large global suppliers and in geographies with administered procurement.

What drives influenza vaccine demand each season?

Core demand engine: annual immunization cycles

• Influenza vaccine is purchased and administered in seasonal windows, with demand typically peaking in the 2 to 3 quarters preceding the peak influenza period.
• The vaccine market behaves like a repeat-purchase program rather than a one-time launch market, which makes prior-year inventory behavior a major determinant of the following year’s pricing and rebate intensity.

Government and payer purchasing is the pricing center of gravity

• In many markets, especially the US, Europe, and parts of Asia-Pacific, procurement is driven by government recommendations and tender processes rather than pure payer incentives.
• This creates a pricing dynamic where net price is heavily influenced by:
  • tender terms (quantity commitments, delivery schedules)
  • contract duration and renewal structure
  • supply allocation and penality clauses
  • hospital and pharmacy channel contracting

Antigen matching and formulation changeover affect perceived value

• Influenza vaccine effectiveness is impacted by antigenic match, but product economics are also tied to the annual antigen strain selection process.
• New or updated strains can shift competitive intensity in specific geographies if certain suppliers secure procurement early based on confidence in manufacturing throughput and compliance.

Supply constraints and manufacturing lead times are financial variables

• Influenza vaccine production requires months of lead time, with capacity tied to egg supply (for egg-based products), cell line readiness (cell-based), or proprietary manufacturing platforms (recombinant).
• When supply tightens in a given season, prices and margins improve. When supply expands, discounts and rebates rise.

How do category and technology shifts change competitive economics?

Influenza vaccines are increasingly segmented by platform type. Platform mix impacts unit economics through manufacturing yields, cost of goods, and regulatory friction.

Technology stack and typical economic implication

Vaccine type (platform)	Primary manufacturing dependency	Economic impact on season revenue	Competitive implication
Egg-based	Egg supply and process throughput	More sensitive to egg availability and scaling	Often highest installed base; price competition stronger in tenders
Cell-based	Cell culture capacity and facility readiness	Can benefit from capacity independence from egg constraints	Supports supply smoothing in some markets
Recombinant	Bioprocess platform and platform scale	Strong differentiation in supply planning	Often commands premium where payers value consistent supply

Net effect: platform leaders can protect margins when supply is constrained because they are better positioned in the procurement negotiation cycle.

What is the financial trajectory pattern for influenza vaccines?

Revenue trajectory: seasonal baseline with contract-driven step changes

Influenza vaccine revenue typically follows a repeat seasonal cadence. The “shape” of the financial trajectory is often driven by:

• early-season booking (large government tenders)
• late-season catch-up purchasing when coverage targets are not met
• stock correction after prior year inventory imbalances

Margin trajectory: capacity and mix determine profit

Influenza vaccines usually show:

• improving gross margin when supply is tight and net price is maintained
• compressing gross margin when supply is abundant and buyers push down net price
• profit concentration among suppliers with broad distribution and stable manufacturing reliability

Working capital: inventory and receivables matter more than R&D spend

Compared with oncology or gene therapy, influenza vaccine financials are less R&D-dense and more:

• logistics heavy (cold chain, regional distribution)
• working-capital sensitive (inventory build ahead of season)
• contract governance sensitive (returns, recall exposure, and allocation)

Channel volatility is material

A practical financial pattern in influenza is that:

• public health ordering often follows policy and funding cycles
• healthcare systems adjust ordering based on forecasted uptake and administered coverage
• retailers and pharmacies follow real-time demand and pricing promotions

How does the competitive landscape shape financial outcomes?

Large-scale global manufacturers dominate annual supply

The influenza vaccine market is concentrated in a small number of multi-product manufacturers with:

• established manufacturing footprint
• regulatory and pharmacovigilance infrastructure
• payer contracting capability
• experience managing seasonal strain updates

Competitive levers that move net price

Suppliers compete through:

• tender readiness (ability to deliver on schedule)
• portfolio depth (multiple presentations and dosing options)
• platform diversity (egg, cell, recombinant)
• distribution reach (institutional contracting and retail availability)

Where are financial upside and downside risks located?

Upside drivers

• Higher net pricing driven by constrained supply
• Larger administered coverage in government campaigns
• Product mix shifts to higher-margin variants or platform types
• Stable manufacturing leading to fewer disruptions and lower cost penalties

Downside drivers

• Supply overshoot leading to higher discounts and rebate pressure
• Antigen mismatch reducing effectiveness perception and slowing uptake
• Policy shifts affecting recommendations, eligibility, or funding
• Manufacturing disruptions increasing costs or reducing shipped volumes

What does procurement policy imply for long-term financial visibility?

Influenza vaccine sales are recurring, which can improve visibility relative to one-time biologic launches. However, procurement policy changes can reset net price and volume.

Key structural features affecting financial trajectory:

• annual tenders with multi-winner strategies can limit price durability
• substitution rules in tenders can shift volume quickly between suppliers
• eligibility expansions (for example, in risk groups) increase addressable demand, but often shift pricing to tender-based competition

What are actionable market dynamics for investors and R&D planners?

1) Treat annual ordering as the core demand variable

Forecasting should weight early government tender capture and institutional ordering timelines. Late-season swings can be value-destructive if inventory misaligns with uptake.

2) Portfolio strategy should match contracting reality

Holding multiple presentations can reduce procurement risk. In practice, contracting favors suppliers that can fulfill different dosing and packaging requirements without schedule slippage.

3) Platform reliability is a margin protection lever

Cell-based and recombinant platforms can act as supply insurance when egg-based scaling tightens or when specific regions face procurement timing constraints.

4) Price erosion risk should be modeled season by season

Net price is not a fixed parameter. It moves with:

• supply balance
• tender aggressiveness
• competitive entries by platform type

How do regulatory and strain-selection cycles influence commercialization timing?

Influenza vaccine commercialization depends on the annual strain selection cycle and regulatory approvals for updated antigen compositions. Financial implication:

• time-to-market risk can impact seasonal capture if approvals are delayed
• manufacturing readiness and release testing capacity drive the ability to meet procurement schedules
• suppliers that execute strain updates efficiently can protect shipped volume and reduce margin leakage from rescheduling

What is the financial trajectory implication for biologic capital allocation?

For established manufacturers, influenza vaccines are a volume and cash-flow product rather than a high-R&D frontier. For newer entrants, the route to sustained financial performance depends on:

• manufacturing scale economics
• evidence of supply reliability
• success in institutional contracting cycles
• platform differentiation aligned with payer procurement objectives

The recurring nature can support steady cash generation, but competitive and procurement dynamics can still compress profits without supply discipline.

Key Takeaways

• Influenza vaccine financials follow a recurring seasonal model with revenue volatility driven by procurement timing, supply balance, and platform mix.
• Net pricing is primarily determined by government tender terms and payer contracting behavior, not launch-style market access.
• Margin is the variable outcome: it expands when supply is tight and the supplier is the reliable tender winner, and it contracts when supply overshoots and buyers demand concessions.
• Platform reliability (egg, cell, recombinant) materially affects both revenue capture and profitability through supply continuity.
• Investor and R&D planning should treat annual ordering, manufacturing readiness, and contract execution as the dominant drivers of the financial trajectory.

FAQs

1. What is the main driver of year-to-year revenue movement in influenza vaccines?
   Tender capture and timing, plus supply-demand balance that drives net price and discounts.

2. Why does platform type influence profitability beyond unit cost?
   Platform reliability affects scheduled shipments, which impacts contract fulfillment and reduces margin leakage from supply disruptions.

3. Do influenza vaccines show strong long-term growth like specialty biologics?
   They typically show stable recurring demand with cyclic revenue changes; growth depends more on coverage policy and mix than on transformative clinical differentiation.

4. What is the biggest operational risk to financial performance?
   Manufacturing readiness and schedule execution relative to strain updates and delivery commitments.

5. How do policy changes affect the financial trajectory most?
   Eligibility expansions can raise volume, but they often reset net pricing through competitive tender pressure.

---

References

[1] WHO. Influenza (Seasonal) - Fact sheet. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
[2] U.S. FDA. Vaccines and Related Biological Products Advisory Committee (VRBPAC) and influenza vaccine strain selection resources. Food and Drug Administration. https://www.fda.gov/advisory-committees/vaccines-and-related-biological-products-advisory-committee
[3] European Medicines Agency (EMA). Guideline and regulatory framework for influenza vaccines. European Medicines Agency. https://www.ema.europa.eu/
[4] CDC. Seasonal Influenza Vaccine Effectiveness and Guidance. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/